Information
54 Changeop-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do, South Korea
+82 70-5227-6001
-
-
Overview
- Summary
- RollingStone Co., Ltd. is an in-vitro diagnostics specialist company established in 2009, focused on the development and manufacturing of rapid and accurate point-of-care diagnostic solutions utilizing innovative Lab-on-a-Chip (LabChip) technology. The company provides comprehensive diagnostic platforms integrating molecular, immunological, and biochemical diagnostic technologies. It has notably contributed to global pandemic response through the development and supply of COVID-19 diagnostic kits. The company changed its name from THE BioMed Co., Ltd. to its current name in September 2025.RollingStone Co., Ltd. is an in-vitro diagnostics specialist company established in 2009, focused on the development and manufacturing of rapid and accurate point-of-care diagnostic solutions utilizing innovative Lab-on-a-Chip (LabChip) technology. The company provides comprehensive diagnostic platforms integrating molecular, immunological, and biochemical diagnostic technologies. It has notably contributed to global pandemic response through the development and supply of COVID-19 diagnostic kits. The company changed its name from THE BioMed Co., Ltd. to its current name in September 2025.
- Key Products/Technologies
- Lab-on-a-Chip (LabChip) Technology: A core technology enabling automation and high-throughput screening by integrating multiple laboratory functions onto a single chip for extremely small fluid volumes. This innovative on-site diagnostic technology overcomes limitations of existing equipment and reagents.Lab-on-a-Chip (LabChip) Technology: A core technology enabling automation and high-throughput screening by integrating multiple laboratory functions onto a single chip for extremely small fluid volumes. This innovative on-site diagnostic technology overcomes limitations of existing equipment and reagents.
- Molecular Diagnostics Solutions: A product line including nucleic acid extraction equipment, gene amplification equipment, reagents, and lab chips. Utilization of integrated POCT systems (Sample Prep + rt-PCR) and real-time PCR technology for disease pathogen diagnosis. Development of kits compatible with LabChip-based Veri-Q PCR 316 and tube-type PCR devices such as ABI 7500 and CFX96.Molecular Diagnostics Solutions: A product line including nucleic acid extraction equipment, gene amplification equipment, reagents, and lab chips. Utilization of integrated POCT systems (Sample Prep + rt-PCR) and real-time PCR technology for disease pathogen diagnosis. Development of kits compatible with LabChip-based Veri-Q PCR 316 and tube-type PCR devices such as ABI 7500 and CFX96.
- Immunological Diagnostics Solutions: Development and supply of immunodiagnostic devices and kits. Provision of fast, simple, and cost-effective diagnostic methods for qualitative and quantitative detection of immunological factors. Development of COVID-19 Antigen Rapid Test (VERI-Q COVID-19 Ag Rapid Test) and IgG/IgM Rapid Test.Immunological Diagnostics Solutions: Development and supply of immunodiagnostic devices and kits. Provision of fast, simple, and cost-effective diagnostic methods for qualitative and quantitative detection of immunological factors. Development of COVID-19 Antigen Rapid Test (VERI-Q COVID-19 Ag Rapid Test) and IgG/IgM Rapid Test.
- Biochemical Diagnostics Solutions: Possession of a diverse product range including complex diagnostic devices, anemia meters, blood glucose meters, medical devices, and strips. Offering multi-detection meters (glucose, cholesterol, hemoglobin) for comprehensive monitoring of chronic metabolic disease factors.Biochemical Diagnostics Solutions: Possession of a diverse product range including complex diagnostic devices, anemia meters, blood glucose meters, medical devices, and strips. Offering multi-detection meters (glucose, cholesterol, hemoglobin) for comprehensive monitoring of chronic metabolic disease factors.
- COVID-19 Diagnostic Kits: Development and supply of real-time PCR kits (nCoV-QS, nCoV-QM, nCoV-OM, nCoV-VM) targeting SARS-CoV-2 (ORF3a, N genes). Support for various sample types including nasopharyngeal, oropharyngeal swabs, sputum, and saliva. Products with major international approvals such as FDA EUL, CE, MFDS, and ANVISA.COVID-19 Diagnostic Kits: Development and supply of real-time PCR kits (nCoV-QS, nCoV-QM, nCoV-OM, nCoV-VM) targeting SARS-CoV-2 (ORF3a, N genes). Support for various sample types including nasopharyngeal, oropharyngeal swabs, sputum, and saliva. Products with major international approvals such as FDA EUL, CE, MFDS, and ANVISA.
- Core Advantages
- Innovative Lab-on-a-Chip (LabChip) Technology: Securing a competitive edge based on proprietary LabChip technology for rapid and accurate on-site disease diagnosis. Implementation of innovative technology surpassing the limitations of existing equipment and reagents.Innovative Lab-on-a-Chip (LabChip) Technology: Securing a competitive edge based on proprietary LabChip technology for rapid and accurate on-site disease diagnosis. Implementation of innovative technology surpassing the limitations of existing equipment and reagents.
- Provision of Comprehensive In-Vitro Diagnostic Solutions: Capability to offer integrated solutions for various disease diagnoses by converging molecular, immunological, and biochemical diagnostic technologies. Technical expertise covering multiple diagnostic methods within a single platform.Provision of Comprehensive In-Vitro Diagnostic Solutions: Capability to offer integrated solutions for various disease diagnoses by converging molecular, immunological, and biochemical diagnostic technologies. Technical expertise covering multiple diagnostic methods within a single platform.
- Expertise in Point-of-Care Testing (POCT): Establishment of a strong position in the POCT market through the development of compact and portable PCR devices. Enhanced user convenience through the provision of quick and accurate test results.Expertise in Point-of-Care Testing (POCT): Establishment of a strong position in the POCT market through the development of compact and portable PCR devices. Enhanced user convenience through the provision of quick and accurate test results.
- Global Market Expansion and Partnerships: Establishment of a joint research institute and joint venture with the University of Indonesia. Agreement for an advanced production facility site within the Saudi-Korean Industrial Village. Acquisition of a US in-vitro diagnostics company and receipt of the '10 Million Dollar Export Award', demonstrating active overseas market development efforts.Global Market Expansion and Partnerships: Establishment of a joint research institute and joint venture with the University of Indonesia. Agreement for an advanced production facility site within the Saudi-Korean Industrial Village. Acquisition of a US in-vitro diagnostics company and receipt of the '10 Million Dollar Export Award', demonstrating active overseas market development efforts.
- Continuous Research and Development and Intellectual Property Acquisition: Twice selected as an 'Excellent Company for Job Invention Compensation' by the Korean Intellectual Property Office (2022, 2024). This demonstrates the company's commitment and capability in innovative technology development and intellectual property protection.Continuous Research and Development and Intellectual Property Acquisition: Twice selected as an 'Excellent Company for Job Invention Compensation' by the Korean Intellectual Property Office (2022, 2024). This demonstrates the company's commitment and capability in innovative technology development and intellectual property protection.
- Experience in Responding to the COVID-19 Pandemic: Development of COVID-19 diagnostic kits and acquisition of major international certifications such as FDA EUL, CE, and ANVISA, proving rapid response capabilities and technological reliability during global pandemic situations.Experience in Responding to the COVID-19 Pandemic: Development of COVID-19 diagnostic kits and acquisition of major international certifications such as FDA EUL, CE, and ANVISA, proving rapid response capabilities and technological reliability during global pandemic situations.
- Target Industrie
- Healthcare and Public Health Industry: Disease diagnosis and management in medical institutions such as hospitals, clinics, and public health centers.Healthcare and Public Health Industry: Disease diagnosis and management in medical institutions such as hospitals, clinics, and public health centers.
- Clinical Diagnostics Market: Application in clinical laboratories for the diagnosis and monitoring of various diseases.Clinical Diagnostics Market: Application in clinical laboratories for the diagnosis and monitoring of various diseases.
- Infectious Disease Diagnosis and Management: Rapid on-site diagnosis and prevention of the spread of infectious diseases like COVID-19.Infectious Disease Diagnosis and Management: Rapid on-site diagnosis and prevention of the spread of infectious diseases like COVID-19.
- Chronic Metabolic Disease Monitoring: Regular self-measurement and management of chronic disease factors such as blood glucose, cholesterol, and hemoglobin.Chronic Metabolic Disease Monitoring: Regular self-measurement and management of chronic disease factors such as blood glucose, cholesterol, and hemoglobin.
- Public Health and Quarantine Systems: Support for the establishment of national and regional infectious disease prevention and control systems.Public Health and Quarantine Systems: Support for the establishment of national and regional infectious disease prevention and control systems.
- Major Markets
- Indonesia, Saudi ArabiaIndonesia, Saudi Arabia
- Europe (Market entry via CE certification)Europe (Market entry via CE certification)
- USA (Market entry via FDA EUL certification and acquisition of US company)USA (Market entry via FDA EUL certification and acquisition of US company)
- Brazil (Market entry via ANVISA certification)Brazil (Market entry via ANVISA certification)
- Certifications/Patents
- Medical Device Manufacturing Approval in South Korea (2013).Medical Device Manufacturing Approval in South Korea (2013).
- Selected as an 'Excellent Company for Job Invention Compensation' by the Korean Intellectual Property Office (2022, 2024). This acknowledges the company's efforts in innovative technology development and intellectual property protection.Selected as an 'Excellent Company for Job Invention Compensation' by the Korean Intellectual Property Office (2022, 2024). This acknowledges the company's efforts in innovative technology development and intellectual property protection.
- Acquisition of major international certifications for COVID-19 diagnostic kits, including FDA EUL (USA), CE (Europe), MFDS (South Korea), and ANVISA (Brazil). This demonstrates the product's compliance with international quality and safety standards.Acquisition of major international certifications for COVID-19 diagnostic kits, including FDA EUL (USA), CE (Europe), MFDS (South Korea), and ANVISA (Brazil). This demonstrates the product's compliance with international quality and safety standards.
- Possession of technology patents related to Lab-on-a-Chip (LabChip) technology, molecular diagnostics, immunological diagnostics, and biochemical diagnostics, alongside continuous R&D activities.Possession of technology patents related to Lab-on-a-Chip (LabChip) technology, molecular diagnostics, immunological diagnostics, and biochemical diagnostics, alongside continuous R&D activities.
Introduction
Location
54 Changeop-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do, South Korea
클릭하여 위치 살펴보기
